James Wassil

Geschäftsführer bei VAXCYTE, INC.

Vermögen: 13 Mio $ am 30.04.2024

54 Jahre

Health Technology

Consumer Services

Commercial Services

Aktive Positionen von James Wassil

Unternehmen	Position	Beginn	Ende
VAXCYTE, INC.	Geschäftsführer	01.12.2019	-

Unternehmen	Position	Beginn	Ende
ICOSAVAX, INC.	Direktor/Vorstandsmitglied	01.06.2022	19.02.2024
ICOSAVAX, INC.	Independent Dir/Board Member	01.06.2022	19.02.2024
PFIZER, INC.	Corporate Officer/Principal	01.05.2015	01.12.2019
NOVARTIS AG	Corporate Officer/Principal	01.08.2008	01.05.2015
Infectious Diseases Society of America Infectious Diseases Society of America Miscellaneous Commercial ServicesCommercial Services The Infectious Diseases Society of America is a non-profit company that provides clinical practice guidelines development and guideline panelists for infectious diseases. The company is based in Arlington, VA and has subsidiaries in the United States. The company specializes in antimicrobial stewardship and have established Antimicrobial Stewardship Centers of Excellence. The CEO of the company is Christopher Busky.	Corporate Officer/Principal	-	-
MERCK & CO., INC.	Vertrieb & Marketing	-	-

University of Notre Dame	Undergraduate Degree
Lehigh University	Graduate Degree

International

Vereinigte Staaten	8
Schweiz	2

Operativ

Corporate Officer/Principal	3
Chief Operating Officer	1
Sales & Marketing	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	4
VAXCYTE, INC.	Health Technology
PFIZER, INC.	Health Technology
NOVARTIS AG	Health Technology
MERCK & CO., INC.	Health Technology

Private Unternehmen	2
Infectious Diseases Society of America Infectious Diseases Society of America Miscellaneous Commercial ServicesCommercial Services The Infectious Diseases Society of America is a non-profit company that provides clinical practice guidelines development and guideline panelists for infectious diseases. The company is based in Arlington, VA and has subsidiaries in the United States. The company specializes in antimicrobial stewardship and have established Antimicrobial Stewardship Centers of Excellence. The CEO of the company is Christopher Busky.	Commercial Services
Icosavax, Inc. Icosavax, Inc. Pharmaceuticals: MajorHealth Technology Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.	Health Technology

Private Unternehmen

Commercial Services

Health Technology